CLYM — Climb Bio Inc
NASDAQ · Healthcare · Biotechnology
$14.70
-$0.12 (-0.81%)
Climb Bio Inc (CLYM) is a biotechnology company listed on NASDAQ. It is led by Aoife M. Brennan BAO, BCh, M.D., MB, MMSc, based in 20 William Street, Wellesley Hills, MA, United States, 02481, with about 17 employees. Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Net income was -$42.3M. CLYM currently screens at market cap $85.8M.
Use this CLYM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CLYM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CLYM SEC filings page. Lician reads the product cache first so this HTML stays unique to Climb Bio Inc even when a live quote feed is slow.
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
CLYM Key Statistics
Market Cap
$85.82M
Volume
1.19M
Previous Close
$16.40
Day Range
$16.75 – $18.33
EPS
-$1.53
Revenue
$0.00
Net Income
-$73.90M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
17
CLYM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$73.90M | -$35.12M | -$45.24M | -$47.48M |
| EPS (Diluted) | -$1.53 | -$1.30 | -$1.72 | -$4.24 |
Total Assets
$217.19M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$87.23M
Operating Cash Flow
-$15.56M
Free Cash Flow
$0.00
Climb Bio Inc Company Information
- Interim Principal Financial Officer, CEO, President & Director
- Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
- Headquarters
- 20 William Street, Wellesley Hills, MA, United States, 02481
- Website
- climbbio.com
- Phone
- 866 857 2596
- IPO / Founded
- 2021-08-10
- Sector
- Healthcare
- Industry
- Biotechnology